Fig. 4

Prophylactic anti-Thy1.2 reduces ILCs and ameliorates colitis in TRAG mice. IP injections of anti-Thy1.2 (1 mg) were administered to TRAG mice from 4–6 weeks of age every 3 days. Anti-Thy1.2 treatment reduced colitis in TRAG mice as indicated by (a) colon length and gross morphology and (b, c) histology. TRAG mice treated with anti-Thy1.2 antibody prior to the development of colitis displayed reduced numbers of colonic mucosal (d) ILC, (e) neutrophils, and (f) inflammatory myeloid cells, compared with control TRAG mice. (Mann–Whitney for (b); T-test for other data) *p < 0.05, p < 0.005. Data represent two independent experiments, mean ± SEM (n = 8–10 mice/group)